Abstracts tagged "patient-reported outcome measures"

Abstract Number: 422 • 2019 ACR/ARP Annual Meeting
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
Vibeke Strand¹, Pankaj Patel ², Naijun Chen ² and Elizabeth M Lesser ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago
Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
Abstract Number: 1250 • 2019 ACR/ARP Annual Meeting
Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?
Emre Bilgin ¹, Timuçin Kaşifoğlu ², Ahmet Omma ³, Cemal Bes ⁴, Muhammet Çınar ⁵, Hakan Emmungil ⁶, Orhan Küçükşahin ⁷, Servet Akar ⁸, Kenan Aksu ⁹, Fatih Yıldız ¹⁰, Nilüfer Kanıtez ¹¹, Abdulsamet Erden ¹², Sezin Turan ¹³, Ediz Dalkılıç ¹⁴, Selime Ermurat ¹⁵, Mutlu Hayran ¹⁶ and Umut Kalyoncu¹⁷, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, ³Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴University of Medical Sciences, İstanbul, Turkey, ⁵University of Medical Sciences, Ankara, Turkey, ⁶Trakya University, Edirne, Turkey, ⁷Liv Hospital, Ankara, Turkey, ⁸Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁹Ege University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁰Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaraş, Turkey, ¹¹Koç University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ¹²Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹³Trakya University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Edirne, Turkey, ¹⁴Uludağ University, Bursa, Turkey, ¹⁵Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey, ¹⁶Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, ¹⁷Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare, chronic and auto-inflammatory disorder with multisystemic involvement. Patient Acceptable Symptom State (PASS) is the highest level of…
Abstract Number: 424 • 2019 ACR/ARP Annual Meeting
A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index
Tyler Harkness¹, Karen Donelan ¹, Xiaoqing Fu ¹, Rachel Wallwork ¹, Cory Perugino ¹, John Stone ² and Zachary Wallace ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) causes symptoms, the severity of which vary by organ involvement. The Responder Index (RI) captures physicians’ judgement of disease activity, but…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
Abstract Number: 428 • 2019 ACR/ARP Annual Meeting
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
Srita Chakka¹, Rebecca Krain ¹, Sarah Ahmed ², Josef Concha ¹, Rui Feng ³ and Victoria Werth ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL).…
Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
Abstract Number: 431 • 2019 ACR/ARP Annual Meeting
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis
Michiel Luijten ¹, Caroline Terwee ², Hedy van Oers ², Mala Joosten ³, Merlijn van den Berg ², Dieneke Schonenberg-Meinema ², Koert Dolman ⁴, Rebecca Ten Cate ⁵, Leo Roorda ⁶, Martha Grootenhuis ³, Marion van Rossum⁷ and Lotte Haverman ², ¹Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands, ⁴Onze Lieve Vrouwe Gasthuis West, Amsterdam, Netherlands, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rehabilitation Research Center | Reade, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam
Background/Purpose: Patient-reported outcome measures (PROMs) are often used to include the patients perspective on treatment (outcome). However, the choice of PROMs is difficult, as there…
Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 433 • 2019 ACR/ARP Annual Meeting
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Ruchi Patel ¹, Valeria Esparza ², Jin-Shei Lai ¹, Elizabeth Gray ¹, Rowland Chang ³, David Cella ³ and Kaveh Ardalan⁴, ¹Northwestern University Feinberg School of Medicine, Chicago, ²University of Illinois-Chicago College of Medicine, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…
Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Joe Zhuo ⁷, Kuan-Hsiang Gary Huang ⁸, Robert Wong ⁷, Sean Connolly ⁸, Yedid Elbez ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Excelya, Boulogne-Billancourt, France, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…
Abstract Number: 435 • 2019 ACR/ARP Annual Meeting
Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
W. Benjamin Nowell¹, Carol Gaich ², Kelly Gavigan ¹, Zhihong Cai ², Anabela Cardoso ², Theresa Hunter ³, Julie Birt ², Jennifer Workman ² and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patient-reported outcomes (PROs) are important indicators of treatment effectiveness and their role is increasing in comparative effectiveness studies. Little is known about PRO measures…
Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting
Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome
Eun Hye Park¹, You-Jung Ha ¹, Eun Ha Kang ¹, Yeong-Wook Song ² and Yun Jong Lee ³, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea
Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
Abstract Number: 441 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
Rosa Morlà¹, R. Castellanos ², Virginia Ruiz-Esquide ³, Julio Ramirez ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁵, Mariam Riad ⁶, Isabel Castrejon ⁶ and Theodore Pincus ⁶, ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Associations of depression with clinical status in RA1 and differences in clinical status in different countries2 have been reported. We compared MDHAQ (multidimensional health…
Abstract Number: 1508 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Lianne Gensler ¹, Jonathan Kay ², Walter P. Maksymowych ³, Nigil Haroon ⁴, Lars Bauer ⁵, Bengt Hoepken ⁵, Natasha de Peyrecave ⁶, Thomas Kumke ⁷ and Atul Deodhar⁸, ¹University San Francisco California, San Francisco, CA, ²UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Pain, fatigue, morning stiffness and impaired sleep are some of the main symptoms contributing to reduced quality of life (QoL) in patients (pts) with…
Abstract Number: 442 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care
Rosa Morlà¹, Mariam Riad ², Virginia Ruiz-Esquide ³, Fernando Espi ⁴, Julio Ramirez ⁵, Nuria Del Castillo ⁶, Jose Gomez-Puerta ⁷, Raimon Sanmarti ⁷, Theodore Pincus ² and Isabel Castrejon ², ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Rush University Medical Center, Chicago, IL, ⁵Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁶Xarxa Social i Sanitaria de Santa Tecla, Tarragona, Spain, ⁷Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) are more likely to report depression than the general population, and depression has been associated with…

1
2
3
…
6
Next Page »